IMAX CEO Richard Gelfond takes temporary medical leave

IMAX Corporation announced that CEO Richard Gelfond is on a temporary medical leave of absence while he receives treatment for pneumonia and recovers.

Rhea-AI Filing Summary

IMAX Corporation announced that CEO Richard Gelfond is on a temporary medical leave of absence while he receives treatment for pneumonia and recovers. During his absence, the company’s senior executives are handling day-to-day operations in coordination with Board Chair Darren Throop and with regular communication with the full Board.

The leadership team highlighted in the announcement includes CFO Natasha Fernandes, Chief Marketing Officer Anne Globe, Chief Legal Officer Rob Lister, and IMAX Theatres President Mark Welton, all of whom have significant tenure with the company. IMAX stated it is providing this update to avoid speculation about Gelfond’s absence from upcoming events and will offer further updates as appropriate.

Insights

Corporate governance and leadership transition analyst

IMAX discloses a temporary CEO medical leave with an experienced team managing operations.

IMAX Corporation has placed CEO Richard Gelfond on a temporary medical leave of absence as he undergoes treatment for pneumonia. The company emphasizes that this is a temporary situation and that he is progressing in his recovery, which limits immediate concerns about a permanent leadership change.

Operationally, day-to-day responsibilities are being managed by senior executives working together with Board Chair Darren Throop and maintaining regular communication with the full Board. The announcement underscores the depth of the leadership bench by listing long-tenured executives, suggesting continuity of strategy and operations while Gelfond is away.

The disclosure notes that IMAX is communicating this update to avoid speculation about Gelfond’s absence from upcoming public and industry events. Future statements from the company may clarify the duration of the leave and any further adjustments, but the current message focuses on stability and continuity during his temporary absence.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

IMAX systems in operation: 1,864 systems Countries and territories: 91 countries and territories

2 metrics

IMAX systems in operation 1,864 systems Operating across 91 countries and territories as of December 31, 2025

Countries and territories 91 countries and territories Global footprint for IMAX systems as of December 31, 2025

Key Terms

temporary medical leave of absence, Regulation FD Disclosure, Named Executive Officers, pneumonia, +1 more

5 terms

temporary medical leave of absence financial

"announced CEO Richard Gelfond is on a temporary medical leave of absence"

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Named Executive Officers financial

"Among the senior executive team are the company’s Named Executive Officers"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

pneumonia medical

"temporary medical leave of absence as he undergoes treatment for pneumonia"

Pneumonia is an infection that inflames the air sacs in the lungs, causing them to fill with fluid or pus and making it hard to breathe — imagine small air balloons in the lungs becoming waterlogged. It matters to investors because outbreaks, treatment costs, hospitalizations and regulatory safety concerns can affect healthcare spending, pharmaceutical and medical-device sales, workforce availability, and insurance payouts, all of which influence company revenues and risk profiles.

Board of Directors financial

"with regular communication with the full Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IMAX (IMAX) announce about CEO Richard Gelfond?

IMAX announced that CEO Richard Gelfond is on a temporary medical leave of absence while he undergoes treatment for pneumonia. The company noted he is receiving strong care and progressing in his recovery, and it will provide further updates as appropriate.

Who is managing IMAX (IMAX) operations during the CEO’s medical leave?

During Richard Gelfond’s temporary medical leave, IMAX’s senior executives are handling day-to-day responsibilities in coordination with Board Chair Darren Throop. They are providing regular updates to the full Board to maintain oversight and continuity in leadership and operations.

Why did IMAX (IMAX) issue a statement about Richard Gelfond’s absence?

IMAX issued the statement to provide transparency and prevent speculation about Richard Gelfond’s absence from upcoming company and industry events. By outlining his temporary medical leave and the interim leadership structure, the company aims to reassure stakeholders about ongoing operational stability.

Which senior executives are highlighted in IMAX’s (IMAX) leadership team?

IMAX highlighted several Named Executive Officers: CFO Natasha Fernandes, Chief Marketing Officer Anne Globe, Senior EVP and Chief Legal Officer Rob Lister, and IMAX Theatres President Mark Welton. Their long tenures at the company underscore depth and experience within the senior leadership group.

Will IMAX (IMAX) provide more updates on the CEO’s medical leave?

IMAX stated it will not provide further comment at this time out of respect for Richard Gelfond’s privacy. However, the company indicated it will provide updates as appropriate, signaling that additional information may be shared when circumstances warrant.

How large is IMAX’s (IMAX) global theatre network?

IMAX reported operating 1,864 systems across 91 countries and territories as of December 31, 2025. This global network supports its position as a leader in immersive entertainment technology for filmmakers, studios, and audiences worldwide.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 05:33 PM Learn about SEC filing dates

0000921582FALSE00009215822026-03-302026-03-300000921582dei:OtherAddressMember2026-03-302026-03-3000009215822025-04-232025-04-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

March 30, 2026

Date of report (Date of earliest event reported)

IMAX Corporation

(Exact Name of Registrant as Specified in Its Charter)

Canada

001-35066

98-0140269

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

2525 Speakman Drive			902 Broadway, Floor 20
Mississauga, Ontario, Canada L5K 1B1			New York, New York, USA 10010
(905) 403-6457			(212) 821-0142

(Address of principal executive offices, zip code, telephone numbers)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, no par value

IMAX

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 30, 2026, IMAX Corporation (the “Company”) issued a press release announcing that Richard Gelfond, the Company’s Chief Executive Officer, is on a temporary medical leave of absence. During his temporary absence, the Company’s senior executives are executing their day-to-day responsibilities in coordination with each other and Darren Throop, Chair of the Board of Directors, with regular communication with the full Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of this current report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release dated March 30, 2026
104						Cover Page Interactive Data File (formatted as inline XBRL).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IMAX Corporation
			(Registrant)
Date: March 30, 2026			By:			/s/ Robert D. Lister
			Name:			Robert D. Lister
			Title:			Chief Legal Officer and Senior Executive Vice President
			By:			/s/ Kenneth I. Weissman
			Name:			Kenneth I. Weissman
			Title:			Deputy General Counsel & Corporate Secretary

3

Exhibit 99.1

IMAX Corporation Announces CEO Richard Gelfond Taking Temporary Medical Leave of Absence

NEW YORK — March 30, 2026 — IMAX Corporation (NYSE: IMAX) today announced CEO Richard Gelfond is on a temporary medical leave of absence as he undergoes treatment for pneumonia. He is receiving outstanding care and progressing in his recovery.

While he receives medical care and recovers, Mr. Gelfond will not be participating in any public or private events for the Company. Consistent with its operating plan in the event of Mr. Gelfond’s temporary absence, the Company’s senior executives are executing their day-to-day responsibilities in coordination with each other and Board Chairman Darren Throop, with regular communication with the full Board of Directors. Among the senior executive team are the company’s Named Executive Officers:

•Natasha Fernandes, EVP and Chief Financial Officer (19 years at IMAX)

•Anne Globe, Chief Marketing Officer (2 years)

•Rob Lister, Sr. EVP and Chief Legal Officer (27 years)

•Mark Welton, President, IMAX Theatres (28 years)

IMAX is issuing this statement to provide transparency and ensure that there is no speculation arising out of Mr. Gelfond not appearing at the Company’s upcoming events, including next week’s industry conferences. Out of respect for Mr. Gelfond’s privacy as he is being treated, IMAX will not provide further comment at this time, but will provide updates as appropriate.

Mr. Throop offered the following statement: “We have a strong, deeply experienced senior executive team who are fully engaged, providing regular updates to the Board, and remain focused as always on the continued growth and success of IMAX. We are all wishing Rich well and a full and speedy recovery.”

About IMAX Corporation

IMAX (NYSE: IMAX) is a global leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems. Filmmakers, studios, and artists worldwide use IMAX to connect with audiences at scale, making its network one of the most powerful platforms for blockbuster events and entertainment.

Headquartered in New York, Toronto, and Los Angeles, IMAX operates 1,864 systems across 91 countries and territories as of December 31, 2025. IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trades on the Hong Kong Stock Exchange under stock code “1970.” IMAX and related marks are trademarks of IMAX Corporation. For more information, visit www.imax.com.

For additional information please contact:

1

Investors: Jennifer Horsley jhorsley@imax.com

Media: Mark Jafar

mjafar@imax.com

2

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 7.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.0 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 15.5 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 27.2 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 16.2 KB